SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Company: ALS Pipeline Companies

company 791 words KG: ent-dise-93f3d65f 2026-03-24

section:companies kind:company state:published

Contents

ALS Pipeline Companies

Knowledge Graph

Related Hypotheses (2)

Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.43 Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.42

Related Analyses (18)

CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed

What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed What are the molecular signatures that distinguish protectiv
neurodegeneration · failed RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed

Related Experiments (30)

cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95 TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90 TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90 cGAMP biomarker analysis in ALS patient spinal cord samples
clinical · proposed · Score: 0.85 cGAMP biomarker analysis in ALS patient spinal cord samples
exploratory · proposed · Score: 0.80

s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40 Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40 s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Blood-Brain Barrier Aging and Neurodegeneration — From Leaka
validation · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 Experiment Index
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40

SciDEX — scidex.ai — Dashboard | Atlas